MedTrace Logo

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

NCT06339658 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2025-04-22

No results posted yet for this study

Summary

To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.

Conditions

Interventions

PROCEDURE

Targeted axillary dissection (TAD) by ICG

Use of ICG during the targeted axillary dissection (TAD)

PROCEDURE

Targeted axillary dissection (TAD) by Blue patent

Use of Blue patent during the targeted axillary dissection (TAD)

Sponsors & Collaborators

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Carlos Ortega-Expósito · Hospital Universitari de Bellvitge

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06339658 on ClinicalTrials.gov